Key facts, as of
As of October 8, 2026, Gilead Sciences (GILD) trades at $146.85, up 25.7% over the past year. Its 52-week range runs from $114.02 to $157.29; the price is 6.6% below that high. It is 6.6% below its all-time high of $157.29, reached in February 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +168.3%, against +312.9% for the S&P 500 (SPY). It sits 7.1% above its 200-day average of $137.07, the usual sign of a long-term uptrend. Its 30-day volatility is 17.9% annualized, which we rate medium risk. It has a dividend yield of 2.23%.
Cite: Portfolio Terminal, "Gilead Sciences (GILD) stock analysis", 2026-10-08. https://portfolio-terminal.com/analyse/gild
Where it trades today
trading 76% of the way up its 52-week range
How the price has moved
How far it is from its record
Gilead Sciences (GILD) is 6.6% below its all-time high of $157.29, reached in February 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +168.3%, against +312.9% for the S&P 500 (SPY).
What to weigh before acting
What Matters Now
- The read on the stock is often driven by pipeline durability, reimbursement pressure, and whether new launches can offset patent cliffs.
- Recent realized volatility sits near 17.9%, below the sector norm of 22.0%, which supports a steadier role inside a diversified portfolio.
- Relative performance versus UNH, JNJ, PFE matters here because leadership inside healthcare rarely stays static for long.
Portfolio Use Case
- GILD is more relevant for investors who want some income support alongside price appreciation, not just pure growth exposure.
- The beta profile suggests it can fit a quality or lower-volatility sleeve more naturally than a high-octane tactical basket.
- The stock becomes more useful when paired with an explicit catalyst watchlist, because sector sentiment can shift quickly around policy, rates, or pipeline news.
What Would Change the View
- The view would need revisiting if peers such as UNH, JNJ, PFE start winning the marginal flow or posting cleaner operating momentum.
Methodology
- Price, market cap, beta, yield, and liquidity fields for GILD come from Yahoo Finance quote and summary data.
- 30-day volatility is calculated from recent daily returns and annualized using a 252-trading-day convention.
- Sector context uses stored benchmark averages for Healthcare so each page compares the ticker against a stable peer baseline rather than against the whole market.
- Peer comparisons use the Portfolio Terminal coverage set and highlight nearby listed alternatives such as UNH, JNJ, PFE.
Sources
- Yahoo Finance quote dataopen →
Live quote, valuation, beta, yield, and volume fields used for GILD. Last refresh: Oct 8, 2026, 10:10 AM.
- Portfolio Terminal methodologyopen →
Explains how analytics, refresh cadence, and portfolio interpretation work across the product.
- Peer set and coverage context
Comparative context for this page is anchored around nearby tracked names such as UNH, JNJ, PFE.
What Gilead Sciences does
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients.…
Employees
17,000
Industry
Drug Manufacturers - General
Headquarters
Foster City, United States
What analysts expect
GILD carries a buy consensus from 26 analysts, with an average price target of $159.27 versus $146.85 today (+8.5%). Targets are estimates and can move quickly after earnings.
Consensus aggregated by Yahoo Finance. Targets are estimates, not forecasts.
How the business is doing
GILD generated $30.46B in trailing revenue (10.2% year over year), with a -10.6% net margin, and $9.77B of free cash flow, against $21.36B of net debt.
The numbers, year by year
| Fiscal year | Revenue | Gross profit | Operating income | Net income | EPS | Free cash flow |
|---|---|---|---|---|---|---|
| 2025 | $29.44B | $23.21B | $11.70B | $8.51B | $6.84 | $9.46B |
| 2024 | $28.75B | $22.50B | $10.60B | $480.00M | $0.38 | $10.30B |
| 2023 | $27.12B | $20.62B | $8.84B | $5.67B | $4.54 | $7.42B |
| 2022 | $27.28B | $21.62B | $10.97B | $4.59B | $3.66 | $8.34B |
When it reports next
Estimates aggregated by Yahoo Finance. Dates move and estimates change until the report lands.
Which ETFs hold it
GILD is in 10 of the 30 ETFs we track. It weighs most in XLV: 3.01% of the fund, holding #8 of 62.
Famous investors who hold it
GILD is in the latest 13F of 2 of the 15 famous investors we follow. Renaissance Technologies (Founded by Jim Simons) holds the most of it: 0.39% of the portfolio, position #35 of 2,931, as of Q2 2026.
How it sits in healthcare
Defensive sector including pharmaceuticals, biotech, medical devices, and healthcare services.
The companies it competes with
GILD beside the healthcare names it is usually measured against.
What the chart is saying
In an uptrend, pressing toward $153.38 resistance.
uptrend- Price is 2.0% above its 50-day average and 7.1% above its 200-day.
- The 50-day crossed above the 200-day on 2026-08-27 (a “golden cross”).
- RSI at 50 is neither stretched nor washed out.
- The nearest ceiling is $153.38 (+4.4%), the nearest floor $142.99 (-2.6%).
A description of the chart, not advice. Indicators describe what the price has done; none of them knows what it does next.
Questions people ask about it
Is GILD a good investment in 2026?
Gilead Sciences operates in the Healthcare sector. Check our real-time metrics above for current valuation.
What is the risk level of GILD?
Based on 30-day volatility of 17.9%, GILD has MEDIUM risk. Beta of 0.33 indicates lower sensitivity to market movements than average.
Does GILD pay dividends?
Yes, Gilead Sciences has a dividend yield of 2.23%.
How far is GILD from its all-time high?
Gilead Sciences is 6.6% below its all-time high of $157.29, reached in February 2026. Over the 10 years to the end of September 2026, with dividends reinvested, it returned +168.3%, against +312.9% for the S&P 500 (SPY).
Which ETFs hold GILD?
10 of the 30 popular ETFs we track hold Gilead Sciences. The largest weights: XLV (3.01%), QQQ (0.78%), VIG (0.77%), QQQM (0.76%) and VYM (0.73%). Measured on each issuer's full holdings file, dated August 31 to October 1, 2026.
How much of VOO is GILD?
0.27%, as of August 31, 2026: GILD is holding #64 of 505 in Vanguard's file for VOO. $1,000 in VOO puts about $2.75 in Gilead Sciences.
Which famous investors own GILD?
Renaissance Technologies (0.39% of Founded by Jim Simons's 13F) and Ray Dalio (0.15% of Bridgewater Associates's 13F), according to their latest Form 13F filings with the SEC (Q2 2026). A 13F lists US long positions 45 days after the quarter ends, so it can be out of date.
What is the analyst price target for GILD?
The average analyst price target for Gilead Sciences (GILD) is $159.27 based on 26 analyst estimates, about 8.5% above the current price of $146.85. The published range runs from $123.00 to $180.00.
How much revenue does GILD generate?
Gilead Sciences reported $30.46B in trailing twelve-month revenue. Revenue growth is running at 10.2% year over year. Net margin sits at -10.6%. Figures are aggregated from company filings by Yahoo Finance and refresh on an hourly cadence.
Compare GILD with anything
Five years side by side: what $10,000 became, how far each fell, whether they move together.